Mizuho Reiterates Buy Rating for LivaNova (NASDAQ:LIVN)

LivaNova (NASDAQ:LIVN)‘s stock had its “buy” rating reiterated by equities research analysts at Mizuho in a note issued to investors on Wednesday, Benzinga reports. They presently have a $75.00 price objective on the stock. Mizuho’s target price would suggest a potential upside of 34.07% from the company’s previous close.

LIVN has been the topic of several other research reports. Robert W. Baird boosted their price target on LivaNova from $56.00 to $62.00 and gave the stock a “neutral” rating in a research report on Thursday, February 22nd. Barclays increased their price target on LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $72.00 target price on shares of LivaNova in a research report on Wednesday, March 20th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $64.40.

LivaNova Stock Up 0.1 %

Shares of LIVN stock opened at $55.94 on Wednesday. The firm has a market cap of $3.02 billion, a PE ratio of 174.82 and a beta of 0.89. LivaNova has a 12 month low of $41.87 and a 12 month high of $59.86. The stock has a 50 day moving average of $52.14 and a 200-day moving average of $50.64. The company has a quick ratio of 2.51, a current ratio of 2.95 and a debt-to-equity ratio of 0.44.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.10. The company had revenue of $310.10 million during the quarter, compared to analyst estimates of $287.65 million. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The firm’s quarterly revenue was up 12.8% compared to the same quarter last year. During the same period last year, the company posted $0.81 earnings per share. On average, equities analysts predict that LivaNova will post 3.01 EPS for the current year.

Institutional Investors Weigh In On LivaNova

Several institutional investors have recently bought and sold shares of LIVN. US Bancorp DE raised its position in LivaNova by 12.4% during the second quarter. US Bancorp DE now owns 2,069 shares of the company’s stock valued at $106,000 after acquiring an additional 229 shares in the last quarter. Arizona State Retirement System grew its stake in shares of LivaNova by 1.8% during the 3rd quarter. Arizona State Retirement System now owns 15,309 shares of the company’s stock worth $810,000 after acquiring an additional 264 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in LivaNova by 1.1% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 28,970 shares of the company’s stock valued at $1,810,000 after purchasing an additional 308 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of LivaNova by 16.7% in the second quarter. PNC Financial Services Group Inc. now owns 2,853 shares of the company’s stock worth $147,000 after purchasing an additional 408 shares during the period. Finally, Headlands Technologies LLC grew its position in LivaNova by 33.3% in the fourth quarter. Headlands Technologies LLC now owns 1,807 shares of the company’s stock valued at $93,000 after acquiring an additional 451 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.